

The *Galanin Receptor 1* Gene Associates with Tobacco Craving in Smokers Seeking Cessation Treatment

Adriana Lori¹, Yilang Tang¹, Stephanie O'Malley², Marina R Picciotto², Ran Wu², Karen N Conneely¹ and Joseph F Cubells^{*1,3}

¹Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA; ²Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA; ³Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA

Craving for tobacco is a major challenge for people with nicotine dependence (ND) who try to quit smoking. Galanin (GAL) and its receptors (GALRs) can alter addiction-related behaviors and are therefore good candidates for modulators of behavioral parameters associated with smoking. We performed a genetic association study in 486 subjects (432 European American, EA) recruited for smoking cessation trials. Twenty-six candidate genes for ND-related phenotypes were selected based on the literature. Subjects were assessed using the Minnesota Withdrawal Scale (MWS), which included a specific item for craving, the Fagerström Scale of Nicotine Dependence (FTND), and other ND-related instruments. One single-nucleotide polymorphism (SNP) in *GALR1*, rs2717162, significantly associated with severity of craving in EA samples ($p = 6.48 \times 10^{-6}$) and in the combined sample ($p = 9.23 \times 10^{-6}$). Individuals with TT and TC genotypes had significantly higher craving scores than CC subjects. We also observed that SNPs in the *CHRNA5* locus, rs16969968 and rs684513, which have been associated with ND-related phenotypes in previous studies, were nominally associated with FTND scores, although these results did not meet Bonferroni-adjusted criteria for experiment-wide significance. Our findings suggest that variation at *GALR1* associates with differences in the severity of past craving for tobacco among smokers motivated to quit. Taken together with preclinical evidence, these results, if replicated, suggest that GAL and GALRs may be useful therapeutic targets for the pharmacological treatment of ND. Our results also confirm previously reported associations between variation at *CHRNA5* and ND.

Neuropsychopharmacology (2011) **36**, 1412–1420; doi:10.1038/npp.2011.25; published online 23 March 2011

Keywords: craving; nicotine dependence; smoking; *GALR1*; Minnesota Withdrawal Scale; Fagerström Test for Nicotine Dependence

INTRODUCTION

Cigarette smoking represents the most important source of preventable morbidity and premature mortality worldwide. Individual differences in smoking behavior can be attributed to genetic as well as to environmental factors. Twin studies have shown that a variety of nicotine-dependence (ND)-related phenotypes are substantially heritable, including ND and smoking persistence (h^2 between 46 and 69%) (Maes *et al*, 2004; True *et al*, 1997; Haberstick *et al*, 2007; Li *et al*, 2003), failed smoking cessation (Xian *et al*, 2003), and various withdrawal symptoms (Xian *et al*, 2003; Pergadia *et al*, 2006). Linkage studies (Li, 2008), candidate-gene association studies, and more recently genome-wide association studies (GWAS) have been used to identify genes

associated with ND. The most remarkable results from GWAS and follow-up candidate-gene studies implicate a gene cluster on chromosome 15q.24–15q.25 containing *CHRNA5*, *CHRNA4*, and *CHRN4*, which respectively encode $\alpha 5$, $\alpha 3$, and $\beta 4$ subunits of the nicotinic acetylcholine receptors (Bierut *et al*, 2008, 2009; Stevens *et al*, 2008; Saccone *et al*, 2007; Li *et al*, 2009; Thorgeirsson *et al*, 2008; Hung *et al*, 2008; Berrettini *et al*, 2008; Weiss *et al*, 2008). Associations between these genes and ND have been replicated using several different measures of ND. An association between variation at these loci and risk for lung cancer has also been reported (Thorgeirsson *et al*, 2008; Hung *et al*, 2008). Although initial studies were conducted in subjects of mainly European descent, more recent studies have confirmed associations between variation within the *CHRNA5/A3/B4* gene cluster and ND-related phenotypes in African-American (Saccone *et al*, 2009; Li *et al*, 2009) and Asian populations (Li *et al*, 2010).

Despite widespread public knowledge of the harmful consequences of smoking, and several interventions (including medications) available for ND, about 27% of individuals in the United States continue to use tobacco

*Correspondence: Professor JF Cubells, Department of Human Genetics, Emory University School of Medicine, 615 Michael Street, Suite 301, Atlanta, GA 30322, USA, Tel: +1 404 727 2005, Fax: +1 404 727 5764, E-mail: jcubell@emory.edu
Received 17 November 2010; revised 19 January 2011; accepted 2 February 2011

regularly (World Health Organization, 2008). Craving has been suggested to be among the most important acute factors contributing to unsuccessful quitting or smoking relapse (Tiffany *et al*, 2009; Aubin *et al*, 2010; Killen *et al*, 2006; Killen and Fortmann, 1997; Piasecki, 2006), but it remains understudied. For example, no clear data on heritability of tobacco craving are available. However, a study of craving for sweet foods in 663 twin pairs (Keskitalo *et al*, 2007) found that additive genetic factors explain ~38% of the variance of such craving. This estimate is within the range typical of a variety of addiction-related phenotypes, and provides at least suggestive evidence that genetic factors may be important in tobacco craving as well.

The main foci of most ND-related genetic studies have been the diagnosis of ND according to DSM-IV or other criteria, or ND-related symptoms such as scores on the Fagerström Scale of Nicotine Dependence (FTND), the number of cigarettes smoked per day (CPD), or cotinine levels (Greenbaum and Lerer, 2009). To date, candidate-gene studies focusing on cessation-related phenotypes, such as craving (Perkins *et al*, 2009; Baker *et al*, 2009; Erblich *et al*, 2004) or withdrawal symptoms (Stern *et al*, 2007; Conti *et al*, 2008; Pergadia *et al*, 2009; Perkins *et al*, 2009; Baker *et al*, 2009), have not yielded compelling positive results. Finding genes associated with craving or other cessation-related phenotypes may help identify new strategies to help people quit smoking.

Recently, it has been shown that several genes that affect feeding can also be involved in drug reward; galanin (*GAL*) and neuropeptide Y (*NPY*) are among these genes (Zachariou *et al*, 2001; Fulton *et al*, 2006). *GAL* in particular can inhibit dopamine and norepinephrine release and may therefore modulate the rewarding properties of nicotine and other drugs of abuse (Robinson and Brewer, 2008; Melnikova *et al*, 2006; Narasimhaiah *et al*, 2009). *GAL* and its receptors have been shown to modulate behaviors such as conditioned place preference, locomotor activation, and withdrawal responses, in studies of addictive drugs in animal models (Zachariou *et al*, 1999, 2000; Hawes *et al*, 2008). In human beings, a nominally significant association between a single-nucleotide polymorphism (SNP) in the *GAL* locus and heroin addiction was recently observed (Levrán *et al*, 2008), and a SNP in *GALR3*, encoding the type-3 *GALR*, has been reported to associate with alcoholism (Belfer *et al*, 2007).

The current case-only candidate gene study was conducted to evaluate a variety of candidate loci and their associations to phenotypes relevant to subjective responses to tobacco, and the ability to quit smoking, assessed at baseline in smokers seeking cessation treatment. Candidate genes were chosen based on the neurobiology of ND, and previous reports of genetic associations. Our results suggest an association between variation at the *GALR1* locus and baseline craving for tobacco in smokers seeking cessation treatment.

MATERIALS AND METHODS

Samples

Six hundred and eleven subjects were recruited from three smoking cessation trials at the Yale University

Transdisciplinary Tobacco Use Research Center (TTURC; Toll *et al* (2007a, 2010) and O'Malley *et al* (2006)). Common inclusion criteria for admission into the studies were a minimum age of 18 years, fluency in English, weight of least 45 kg, and daily cigarette smoking (10 or more; Toll *et al* (2010)) and an expired carbon monoxide level of greater than or equal to 10 p.p.m. Exclusion criteria included current serious neurological, psychiatric, or medical illness, current dependence on illicit drugs of abuse, and for women, being pregnant or nursing, or being sexually active without using reliable birth control. Additional study-specific criteria can be found in the original reports (O'Malley *et al*, 2006; Toll *et al*, 2010). All subjects were prescreened by phone; this report is based on data provided by subjects who consented at the in-person intake evaluation whether or not they ultimately met all eligibility criteria. For the association tests presented here, we restricted analyses to individuals whose self-reported race was European American (EA) or African American (AA).

Assessments

At intake sessions, participants completed questionnaires and interviews assessing demographics (age, gender, race, weight, height, marital status, numbers of children, education level), personal and family history of smoking and alcohol use, mood, and other areas of functioning.

Written informed consent for participation, including explicit consent to donate blood samples for use in genetic studies, was obtained from each subject, following procedures approved by the Institutional Review Board (IRB) of Yale University School of Medicine. The Emory University IRB approved laboratory and statistical analysis of de-identified DNA samples and data.

Scales for Craving and ND

The Minnesota Withdrawal Scale (MWS) is an 8-item questionnaire, which assesses craving (Toll *et al*, 2007b), plus seven symptoms of nicotine withdrawal listed in the DSM-IV (Gmitrowicz and Kucharska, 1994) (irritability, frustration, or anger, anxiety, difficulty concentrating, restlessness, increased appetite or weight gain, depressed or sad mood, insomnia or sleep problems) (Hatsukami *et al*, 1992, 1998; Hughes and Hatsukami, 1986). Each symptom is rated from 0 (none) to 4 (severe). We administered the MWS to each participant at intake (ie, before quitting). The wording of the MWS instructions was designed to assess each subject's experience during a previous quit attempt: 'Listed below are a number of symptoms some people have experienced when they have cut down their smoking in an effort to quit. Please rate the severity of each of the symptoms listed below that you experienced DURING A PRIOR QUIT ATTEMPT.'

Severity of ND was assessed using the FTND (Heatherton *et al*, 1991), number of CPD, plasma cotinine concentration, and age at first cigarette. The FTND is a 10-item questionnaire (scale 0–10) that evaluates symptoms of ND, including smoking quantity (SQ) and the behaviors related to the individual's urge to smoke ('how soon after waking up do you smoke your first cigarette' ... 'do you smoke if you are so ill that you are in bed most of the day'). Cotinine,

Table 1 List of the Candidate Genes used in the Candidate Association Study

Candidate genes	Gene symbol
Acetylcholine receptor genes and its regulator	CHRNA4, CHRNA5, CHRN3, UBQLN1
Dopamine receptors pathways	DRD1, DRD2, DRD3, DRD4, DRD5, COMT, ARVCF, DBH, TH, DDC, MAOA, SLC6A3 (DAT), SLC6A2
Published evidence from human studies	NRXN1, NRXN3, CNR1
Neurobiological and pharmacological investigation	GAL, GALRI, GALR3, NPY, FA2H, ADRA1A

A detailed description of all genes and tag SNPs is listed in Supplementary Table 1.

the main metabolite of nicotine, is a biomarker of nicotine intake and was measured from blood samples using a modified HPLC procedure (Hariharan *et al*, 1988).

Bioinformatics and SNP Selection

Twenty-six genes were selected for this genetic association study based on recent pharmacological and GWA findings (Table 1, Supplementary Table 1). SNPs were identified using publicly available online resources, including the UCSC Genome Bioinformatics Site (<http://genome.ucsc.edu/>), HAPMAP (hapmap.org), and SNPbrowser 2.0 (Applied Biosystems, Foster City, CA) software. Selection of tagging SNPs to cover a particular gene was carried out using HAPMAP and SNPBrowser (ABI). The criteria for choosing tag SNPs were as follows: (1) having a proxy (surrogate) SNP with $r^2 \geq 85\%$ for any SNP in the region that (2) had a minor allele frequency (MAF) $\geq 5\%$. We also made sure to include non-synonymous SNPs regardless of MAF or pair-wise r^2 with neighboring SNPs. For NRXN1 and NRXN3, which are very large genes, we only selected SNPs that have been reported in the literature as potentially associated with ND (Bierut *et al*, 2007; Novak *et al*, 2009; Nussbaum *et al*, 2008) or that could be functional variants. Supplementary Table 1 shows a list of the genes and which SNP selection approach was used for each. A total of 145 SNPs were selected (Supplementary Table 1).

Ancestry Informative Markers

To address potential artifacts due to population stratification, we typed 106 Ancestry Informative Markers (AIMs) from a previously described panel (Fejerman *et al*, 2008) that effectively discriminates European, African, and Native American origins, in a subsample of 358 subjects from the three smoking cessation trials.

Genotyping

Genomic DNA was extracted from whole blood using a Mag-Bind SQ Blood DNA kit (Omega Bio-Tek, Norcross, GA) on a KingFisher Flex Magnetic Particle Processor (Thermo Scientific, Waltham, MA) following the manufacturer's instructions. DNA samples (5 μ g) were arrayed in

384-well plates using a Biomek FX liquid handling system and dried overnight. For quality control, each plate contained at least two blanks, two repeat samples, and two lab control samples known to be of high DNA quality. Genotyping was performed for all the SNPs using Sequenom MassArray platform (Ehrich *et al*, 2005; Gabriel *et al*, 2009). PCR primers and extension primers were automatically designed using MassArray Assay Designer software and ordered from Integrated DNA Technologies (Coralville, IA; primer sequences are available on request). Genotype calls were made using the Spectrotyper software (Sequenom) and then downloaded into a BC-Gene database (<http://www.bcplatforms.com>), which ran standard quality control analyses, including evaluation of Hardy-Weinberg equilibrium, call rates, and minor allele frequencies.

Genotypes for the GALRI SNP rs2717162 were confirmed using the 5'-exonuclease (TaqMan) method. The Taqman assay kit and genotyping reagents were ordered from Applied Biosystems. Genotyping was performed on an ABI 7900HT system, with samples arrayed in 384-well plates. Six discordant genotypes were eliminated from the analyses.

Data Cleaning and Quality Control

Candidate genes. Twenty-one samples of the initial 611 samples failed: 590 samples were used in the final analyses. From the initial 145 SNPs, 11 did not amplify and/or significantly deviated from Hardy-Weinberg equilibrium and/or had a call rate lower than 90%; 24 SNPs turned out not to be polymorphic and 29 had an MAF minor of < 0.02 ; a total of 81 SNPs were used for our analyses. The allele-frequency data observed in our sample were similar to population data reported in NCBI (Supplementary Table 2).

AIMs. Five samples were excluded owing to genotyping failure. For the AIMs, 10 SNPs with a call rate below 90% or poor QC metrics were discarded from the subsequent analyses.

Statistical Analysis

Candidate genes. A univariate general linear model (GLM) was run for each SNP using the following dependent variables: (i) MWS mean; (ii) craving score; (iii) FTND sum; (iv) salivary cotinine level; (v) age at first cigarette; and (vi) CPD. We chose a GLM over the alternative of testing additive, dominant, and recessive models for each SNP to minimize multiple testing. The following variables were assessed for association with the outcomes, and used as covariates when appropriate: age, sex, BMI, education, and estimated proportion of European chromosomal ancestry (see below). For analyses that included both EA and AA samples, we performed a stratified analysis by including a covariate for EA vs AA. For important results, we also used permutation tests to compute empirical p -values. We generated 1 000 000 permuted data sets in which the values of the dependent variable were randomly re-assigned to individuals within each race, and computed the empirical p -value as the proportion of permuted tests for which the F statistic exceeded the original. To maintain an experiment-wide significance level of 0.05, we set α to 0.00010

(0.05/(81 × 6)), to correct for multiple testing (81 SNPs and six phenotypic outcomes). All statistical analyses were implemented in SPSS (17.0) or R.

In silico analysis. Linkage disequilibrium (LD) plot for SNPs in *GALR1* in the EA subsample were prepared using Haploview 4.1, and compared with those derived from the CEU data available in HAPMAP (<http://hapmap.ncbi.nlm.nih.gov/>); r^2 was used to evaluate LD between SNPs. Predicted canonical transcription factor analyses in the region surrounding the significant SNP (rs2717162 T/C) were performed using the MatInspector software by Genomatix (www.genomatix.de/cgi-bin/eldorado).

AIMs. We used the Structure software (Pritchard *et al*, 2000a) and the above-described AIMs to analyze population stratification. Structure estimates proportions of chromosomal ancestry based on K (the number of source populations). As recommended in the documentation of the software, we ran analyses with a range of values for K (in this case, between 1 and 4), with 10 000 and 100 000 iterations for burn-in. All other settings were at the default values. For each K , at least three runs were performed with and without using self-reported race data from each individual (Pritchard *et al*, 2000b; Rosenberg *et al*, 2002).

RESULTS

Four hundred and eighty-six smokers (47.8% male, FTND mean ± SD = 5.8 ± 2.1) who underwent evaluation for enrollment in clinical trials for smoking cessation were included in the study. Additional demographic and ND-related phenotypic characteristics of the sample are summarized in Table 2. Level of education associated significantly with five of the six phenotypes of interest (Supplementary Table 3). We therefore used level of education, coded as a three-level variable, as a covariate in our model. The degree of depressive symptoms varied widely in the sample, with total Center for Epidemiological Studies Depression Scores (CES-D) (Radloff, 1977) ranging from 0 to 43 (mean, SD: 9.21 ± 7.22).

First, for the candidate gene study, we performed GLM analyses in the EA subset of the sample ($n = 432$); the sample sizes of other self-reported ethnicities were not large enough to support separate analyses at this stage.

One SNP in the *GALR1* locus (rs2717162) was significantly associated with severity of craving as measured by the MWS in the EA subsample ($p = 6.48 \times 10^{-6}$). A similar direction of association was observed in the AA subsample, but was not significant ($p = 0.57$; Table 3). Analysis of the combined EA and AA samples revealed an association of similar strength to that observed in the EA sample ($p = 9.23 \times 10^{-6}$) (Table 3). Individuals with TT and TC genotypes had significantly higher craving scores than CC subjects in the EA subsample ($p = 7.7 \times 10^{-6}$) and the entire sample ($p = 5.35 \times 10^{-8}$; Figure 1). To evaluate whether the lack of significance in the AA subsample reflected the relatively low power of this subsample, we performed a power analysis using the program QUANTO (Gauderman, 2002a, b), assuming a recessive model (consistent with low craving only in the TT homozygotes). On the basis of an

Table 2 Demography and Phenotype Description of Studied Population

Item (n)	Mean ± SD (%)
Age (486)	43.3 ± 12.0
Sex (486), male	47.1%
Self-identified race (486)	
EA (432)	88%
AA (54)	
Education (475)	
Below high school	187 39.4%
High school to college	173 36.4%
College or higher	115 24.2%
BMI (404)	28.48 ± 6.27
Male	29.49 ± 5.33
Female	27.59 ± 6.89
FTND (479)	5.8 ± 2.1
CPD (379)	24.87 ± 10.16
Years smoked (358)	19.0 ± 12.1

Abbreviations: AA, African American; CPD, cigarette per day; EA, European Americans; FTND, Fagerström Test for Nicotine Dependence.

Table 3 Rs2717162 SNP is Significantly Associated with the Craving Score from the MWS

Type	Significant Co-variate	Race	N	GLM
Craving	Education	EA	377	6.48×10^{-6} *
		AA	43	0.57
		Entire sample	420	9.23×10^{-6} **
MWS	Sex	EA	305	0.011
		AA	43	0.853
		Entire sample	404	0.001

Abbreviations: GLM, general linear model; MWS, Minnesota Withdrawal Scale mean.

GLM in EA, AA, and entire population for rs2717162. In EA and entire population, this SNP was highly associated with craving score reaching a GWAS significance. We also used permutation tests to compute empirical p -values reaching a significance of 10^{-5} .

*Permutation p -value = 2.6×10^{-5} .

**Permutation p -value = 3.2×10^{-5} .

overall mean craving score of 3.3 and SD = 0.85, and a MAF of 0.26, the power of the AA sample ($N = 43$) to detect the observed effect size in a gene-only model at $\alpha = 0.05$ was 0.024; for the EA sample, power was 0.96 and for the overall sample, 0.99. MWS total scores, which included the craving score, were also nominally associated with rs2717162 (Table 3), but did not meet Bonferroni-corrected criteria for experiment-wide significance.

Neither alcohol consumption, alcohol abuse, nor CES-D depression scores were significantly associated with the *GALR1* SNP, and none of those measures accounted for any additional variance in craving scores (data not shown).




Figure 1 Comparison of craving score in smokers with different genotype at rs2717162 (*Galanin Receptor 1*, *GALRI*) in European American (EA), African American (AA) subjects, or in the Entire population (EP). The numbers on the bars are the subjects in each genotype group. The p -values were calculated based on permutations. The CC genotype shows the lowest craving score in the three groups, reaching significance in the EA and EP.

rs2717162 was not in strong LD with any of the other eight SNPs analyzed at *GALRI*, a result consistent with those from HAPMAP. Figure 2 shows a Haploview plot of LD among the *GALRI* SNPs, using r^2 as the measure of LD. The plot was similar to that generated from the CEPH samples in HAPMAP (Figure 2). Using HAPMAP, we analyzed an extended region of *GALRI* (1 Mb) to find other possible SNPs in LD with rs2717162; Figure 3 shows a portion of this area. We observed only one other SNP in LD with both rs2717162 and rs2850878, located in the same intronic region, about 1 kb downstream.

To evaluate the possibility that population stratification accounted for some or all of the above results, 358 subjects were typed at 96 AIMs. After running analyses with K between 1 and 4, the value of K that maximized the estimated model $\ln P(D)$ was $K=2$, with and without data on self-reported population of origin (Pritchard *et al*, 2000a; Falush *et al*, 2007). The model reflected data from self-reported race, very well (Supplementary Figure 1), with proportion of European ancestry 0.855 (SD=0.32) for self-identified EAs and 0.145 (SD=0.32) for self-identified AAs with $K=2$. We used the estimated cluster membership under models of $K=2$ and 3 as covariates in GLM of craving as the dependent variable. The proportion of chromosomal ancestry in either the $K=2$ or 3 models for each single subject (cluster) did not account for any significant proportion of the variance (Supplementary Table 4); rs2717162 in *GALRI* still reached the Bonferroni-corrected threshold for experiment-wide significance after accounting for ancestry proportions ($p = 6.52 \times 10^{-6}$ and 7.5×10^{-6} for $K=2$ and 3, respectively; Supplementary Table 4).

Our analyses did not identify experiment-wide significant associations between any SNP and FTND, cotinine, age of first cigarette, or cigarettes per day in the EA subpopulation

after Bonferroni correction (Supplementary Table 3). However, the GLM revealed nominally significant associations ($p < 0.02$) within the *CHRNA5* locus between both rs16969968 and rs684513, and the two measures of ND (FTND and cotinine level, Supplementary Figure 2).

DISCUSSION

The major finding in this study was that one SNP in the *GALRI* gene strongly associated with self-reported craving for tobacco experienced during a previous quit attempt, as assessed by the MWS. Evidence from previous reports suggests that craving may be one of the most sensitive and consistent predictors of smoking behavior and relapse (Piasecki, 2006). This finding could therefore be important for understanding genetic contributions to smokers' ability to quit once addicted. For the purposes of our study, we analyzed craving separately from other items on the MWS because previous work has suggested that (Hughes and Hatsukami, 1998) craving may reflect distinct central nervous system pathways and genes from other measures (Teneggi *et al*, 2005; Koob and Volkow, 2010).

rs2717162 is an intronic SNP in the *GALRI* gene. Interestingly, *in silico* analysis of 35 bp of sequence surrounding rs2717162 predicted four transcription factor binding sites for the T allele that were not predicted for the C allele. Conversely, the presence of the C allele predicted a distinct transcription factor binding motif (Supplementary Table 5). This observation raises the possibility that rs271762 is a functional variant that influences expression of the gene. The hypothesis that the SNP directly influences gene expression is an intriguing one that will require experimental evaluation in transient-transfection/reporter gene assays, chromatin immunoprecipitation, or other paradigms. Our analysis of the SNP data from this study, and the data available in HAPMAP, shows that there are no known common SNPs in strong LD with rs271762, suggesting the possibility that rs271762 could be directly involved in heritable differences in craving for tobacco. Alternatively, an as-yet undiscovered variant(s), influencing the function of *GALRI* and leading to differences in craving, could be in LD with rs271762. Deep re-sequencing studies in samples from opposite homozygotes at rs271762 are warranted to evaluate that hypothesis.

The association of rs271762 with tobacco craving appears unlikely to be due to population stratification, as the proportion of chromosomal ancestry, estimated using a previously validated panel of AIMs, neither associated with craving score nor reduced the significance of the SNP association when added to the model as a covariate.

GALRI is widely expressed throughout the brain and in particular in the cortico-limbic regions implicated in emotional behavior (Holmes *et al*, 2003). *GAL* is co-expressed with acetylcholine and it can inhibit acetylcholine release. *GAL* inhibits glutamate, but not GABA, release in the hippocampus (for a review see Picciotto *et al* (2010)). We speculate that a functional change in *GALRI* could lead to a decrease in dopamine release in the VTA and a resultant decrease in drug reward. Moreover, *GALRI* is highly expressed in the amygdala; human neuroimaging studies have shown that this brain area, together with the




Figure 2 Linkage disequilibrium (LD) structure of *galanin receptor 1* (*GALRI*) gene in European American (EA) (left) in our sample and based on the data from the HAPMAP project (right). LD matrix of *GALRI* single-nucleotide polymorphisms (SNPs) measured by r^2 for SNPs in EAs (left) and Council on Education for Public Health (CEPH) (right). Each box represents r^2 , % LD between SNP pairs, as generated by Haploview (Whitehead Institute for Biomedical Research). Boxes without numbers represent complete LD; $r^2 = 100\%$. SNP IDs are public database rs numbers. The plot from the EA (left) was similar to that generated from the CEU samples in HAPMAP (right), with no other SNPs in LD with rs2717162.




Figure 3 Linkage disequilibrium (LD) of HAPMAP single-nucleotide polymorphisms (SNPs) in the region surrounding *galanin receptor 1* (*GALRI*). LD matrix of *GALRI* gene and surrounding areas measured by r^2 for SNPs in Council on Education for Public Health (CEPH). Each box represents r^2 , % LD between SNP pairs, as generated by Haploview (Whitehead Institute for Biomedical Research). Boxes in black without numbers represent complete LD; $D' = 100\%$. SNP IDs are public database rs numbers. SNP rs2717162 is circled: it is in LD with only one other SNP located in the same intronic region. Using HAPMAP, it seems there is no other known variant that could explain our finding.

prefrontal cortex, is critical for drug- and cue-induced craving in human beings (Franklin *et al*, 2007). Taken together, these data support the hypothesis that *GALRI* and *GAL* can modulate the craving phenotype.

Few GWAS studies have focused on measures of ND that correspond to the ability to quit smoking, despite the obvious clinical and public health importance of such phenotypes. Uhl *et al* (2007, 2008) identified several candidate genes comparing successful *vs* unsuccessful smoking cessation. Those loci were involved in cell adhesion, enzymatic, transcriptional regulation, and DNA/RNA protein binding. Drgon *et al* (2009) reported a GWAS study comparing individuals who had successfully quit smoking to those who had not, and found some overlap with the work of Uhl and co-workers (2007, 2008) identifying genes involved in cell adhesion and cell-to-cell communication processes. None of these previous studies, to our knowledge, identified *GALRI* as a candidate gene. However, these studies compared two groups (successful *vs* unsuccessful quitters) and none of the previous studies examined craving during a previous quit attempt as the phenotype.

Numerous studies have recently shown an association between SNPs within the *CHRNA5/A3/B4* cluster at 15q24 and several measures of nicotine addiction (Bierut *et al*, 2008, 2009; Stevens *et al*, 2008; Saccone *et al*, 2007; Thorgeirsson *et al*, 2008; Hung *et al*, 2008). Moreover, a recent GWAS meta-analysis using 74 053 subjects, using four smoking phenotypes and a follow-up analyses with more than 140 000 subjects for the most significant regions revealed three loci associated with CPD: rs1051730 in *CHRNA3* (10^{-73}), and rs16969968 (10^{-72}) and rs684513 (10^{-8}) in *CHRNA5* (Tobacco and Genetics Consortium, 2010). Our study supported a nominally significant association between rs16969968 and rs684513 and FTND, but not CPD. Given the extensive data already supporting associations between the foregoing SNPs and ND-related phenotypes, we cautiously conclude that the modest associations observed here may represent true associations even though they did not meet Bonferroni-corrected criteria for experiment-wide significance.

Strengths of this work include the fact that subjects were recruited for smoking cessation studies, and thus represent a unique subpopulation of the smoking population. The carefully assessed phenotypes available from each subject allowed us to examine understudied phenotypes such as withdrawal symptoms and craving, which are germane to the ability to quit. Our results suggest that the measure of craving might be an important phenotype to examine in other samples of ND subjects.

An important limitation of this study was that we did not have a demographically matched control sample of non-smokers, and hence were confined to analyzing within-case phenotypes. We therefore cannot draw any conclusions about the potential association of *GALRI* to ND *per se*. Another limitation is the modest sample size, although we note that the association observed for the *GALRI*-craving association would have approached genome-wide significance in the context of a typical GWAS. Although our sample size was clearly too small to support genome-wide analysis, it was larger than most previous candidate-gene studies (Uhl *et al*, 2010; Conti *et al*, 2008; Kim *et al*, 2009),

and as the power calculations presented above indicate, adequate to detect the effect we observed for *GALRI*. Replication of the result in independent samples is clearly necessary. Finally, the MWS craving item used in this study captured the subject's recollection of craving during previous quit attempts. We focused on that method of assessment because it maximized the number of subjects from whom useful data could be gathered, and hence maximized our statistical power. Future studies of craving rated *during* a quit attempt would be valuable.

In conclusion, the results of this study, together with preclinical evidence, suggest sequence variation at *GALRI* associates with baseline craving for tobacco in smokers motivated to quit. If confirmed, this association would imply that *GAL* and its receptors might be useful therapeutic targets for the pharmacological treatment of ND.

ACKNOWLEDGEMENTS

This study was supported by Yale Transdisciplinary Tobacco Use Research Center (P50AA15632, P50DA13334), K05AA014715; K02DA015766, and the Emory University Training Program in the Neurobiology of Drug Abuse (DA15040). MRP was supported by DA15425. We thank Carolyn Mazure and Sherry McKee for leading the development of the core battery and Elaine Lavelle for data management.

DISCLOSURE

Dr Joseph Cubells is supported by NIMH; NARSAD; NIDA; Roche; Seaside Therapeutics; and consultant Dykema, Gossett, LLP; Barnes and Thornburg, LLP. Dr Stephanie O'Malley is a member of the American College of Neuropsychopharmacology workgroup, the Alcohol Clinical Trial Initiative, sponsored by Eli Lilly, Janssen, Schering Plough, Lundbeck, Glaxo SmithKline, and Alkermes; partner, Applied Behavioral Research; contract, Nabi Biopharmaceuticals Travel; and consultant, Gilead Pharmaceuticals and GlaxoSmithKline. Dr Marina R Picciotto is supported by Grants DA15425, DA14241, DA10455, and MH077681, and by the Charles BG Murphy Chair in Psychiatry at Yale University. All the other authors declare no conflict of interest related to this study.

REFERENCES

- Aubin HJ, Peiffer G, Stoeber-Delbarre A, Vicaut E, Jeanpetit Y, Solesse A *et al* (2010). The French Observational Cohort of Usual Smokers (FOCUS) cohort: French smokers perceptions and attitudes towards smoking cessation. *BMC Public Health* 10: 100.
- Baker TB, Weiss RB, Bolt D, von Niederhausern A, Fiore MC, Dunn DM *et al* (2009). Human neuronal acetylcholine receptor A5-A3-B4 haplotypes are associated with multiple nicotine dependence phenotypes. *Nicotine Tob Res* 11: 785-796.
- Belfer I, Hipp H, Bollettino A, McKnight C, Evans C, Virkkunen M *et al* (2007). Alcoholism is associated with *GALR3* but not two other galanin receptor genes. *Genes Brain Behav* 6: 473-481.
- Berrettini W, Yuan X, Tozzi F, Song K, Francks C, Chilcoat H *et al* (2008). Alpha-5/alpha-3 nicotinic receptor subunit alleles increase risk for heavy smoking. *Mol Psychiatry* 13: 368-373.

- Bierut LJ (2009). Nicotine dependence and genetic variation in the nicotinic receptors. *Drug Alcohol Depend* **104**(Suppl 1): S64–S69.
- Bierut LJ, Madden PA, Breslau N, Johnson EO, Hatsukami D, Pomerleau OF et al (2007). Novel genes identified in a high-density genome wide association study for nicotine dependence. *Hum Mol Genet* **16**: 24–35.
- Bierut LJ, Stitzel JA, Wang JC, Hinrichs AL, Gruzca RA, Xuei X et al (2008). Variants in nicotinic receptors and risk for nicotine dependence. *Am J Psychiatry* **165**: 1163–1171.
- Conti DV, Lee W, Li D, Liu J, Van Den Berg D, Thomas PD et al (2008). Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. *Hum Mol Genet* **17**: 2834–2848.
- Drgon T, Montoya I, Johnson C, Liu QR, Walther D, Hamer D et al (2009). Genome-wide association for nicotine dependence and smoking cessation success in NIH research volunteers. *Mol Med* **15**: 21–27.
- Ehrich M, Bocker S, van den Boom D (2005). Multiplexed discovery of sequence polymorphisms using base-specific cleavage and MALDI-TOF MS. *Nucleic Acids Res* **33**: e38.
- Erblich J, Lerman C, Self DW, Diaz GA, Bovbjerg DH (2004). Stress-induced cigarette craving: effects of the DRD2 TaqI RFLP and SLC6A3 VNTR polymorphisms. *Pharmacogenomics J* **4**: 102–109.
- Falush D, Stephens M, Pritchard JK (2007). Inference of population structure using multilocus genotype data: dominant markers and null alleles. *Mol Ecol Notes* **7**: 574–578.
- Fejerman L, John EM, Huntsman S, Beckman K, Choudhry S, Perez-Stable et al (2008). Genetic ancestry and risk of breast cancer among US Latinas. *Cancer Res* **68**: 9723–9728.
- Franklin TR, Wang Z, Wang J, Sciortino N, Harper D, Li Y et al (2007). Limbic activation to cigarette smoking cues independent of nicotine withdrawal: a perfusion fMRI study. *Neuropsychopharmacology* **32**: 2301–2309.
- Fulton S, Pissios P, Manchon RP, Stiles L, Frank L, Pothos EN et al (2006). Leptin regulation of the mesoaccumbens dopamine pathway. *Neuron* **51**: 811–822.
- Gabriel S, Ziaugra L, Tabbaa D (2009). SNP genotyping using the Sequenom MassARRAY iPLEX platform. *Curr Protoc Hum Genet Chapter Chapter 2*: Unit 2 12.
- Gauderman WJ (2002a). Sample size requirements for association studies of gene–gene interaction. *Am J Epidemiol* **155**: 478–484.
- Gauderman WJ (2002b). Sample size requirements for matched case–control studies of gene–environment interaction. *Statist Med* **21**: 35–50.
- Gmitrowicz A, Kucharska A (1994). Developmental disorders in the fourth edition of the American classification: diagnostic and statistical manual of mental disorders (DSM IV—optional book). *Psychiatr Pol* **28**: 509–521.
- Greenbaum L, Lerer B (2009). Differential contribution of genetic variation in multiple brain nicotinic cholinergic receptors to nicotine dependence: recent progress and emerging open questions. *Mol Psychiatry* **14**: 912–945.
- Haberstick BC, Timberlake D, Ehringer MA, Lessem JM, Hopfer CJ, Smolen A et al (2007). Genes, time to first cigarette and nicotine dependence in a general population sample of young adults. *Addiction* **102**: 655–665.
- Hariharan M, VanNoord T, Greden JF (1988). A high performance liquid chromatographic method for routine simultaneous determination of nicotine and cotinine in plasma. *Clin Chem* **34**: 724–729.
- Hatsukami D, Lexau B, Nelson D, Pentel PR, Sofuoglu M, Goldman A (1998). Effects of cotinine on cigarette self-administration. *Psychopharmacology (Berl)* **138**: 184–189.
- Hawes JJ, Brunzell DH, Narasimhaiah R, Langel U, Wynick D, Picciotto MR (2008). Galanin protects against behavioral and neurochemical correlates of opiate reward. *Neuropsychopharmacology* **33**: 1864–1873.
- Heatheron TF, Kozlowski LT, Frecker RC, Fagerström KO (1991). The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. *Br J Addict* **86**: 1119–1127.
- Holmes A, Kinney JW, Wrenn CC, Li Q, Yang RJ, Ma L et al (2003). Galanin GAL-R1 receptor null mutant mice display increased anxiety-like behavior specific to the elevated plus-maze. *Neuropsychopharmacology* **28**: 1031–1044.
- Hughes J, Hatsukami DK (1998). Errors in using tobacco withdrawal scale. *Tob Control* **7**: 92–93.
- Hughes JR, Bickel WK, Higgins ST (1992). Alcohol and addictions. *Am J Psychiatry* **149**: 1118; author reply 1118–1119.
- Hughes JR, Hatsukami D (1986). Signs and symptoms of tobacco withdrawal. *Arch Gen Psychiatry* **43**: 289–294.
- Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D et al (2008). A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. *Nature* **452**: 633–637.
- Keskitalo K, Tuorila H, Spector TD, Cherkas LF, Knaapila A, Silventoinen K et al (2007). Same genetic components underlie different measures of sweet taste preference. *Am J Clin Nutr* **86**: 1663–1669.
- Killen JD, Fortmann SP (1997). Craving is associated with smoking relapse: findings from three prospective studies. *Exp Clin Psychopharmacol* **5**: 137–142.
- Killen JD, Fortmann SP, Murphy Jr GM, Hayward C, Arredondo C, Cromp D et al (2006). Extended treatment with bupropion SR for cigarette smoking cessation. *J Consult Clin Psychol* **74**: 286–294.
- Kim WJ, Hersh CP, DeMeo DL, Reilly JJ, Silverman EK (2009). Genetic association analysis of COPD candidate genes with bronchodilator responsiveness. *Respir Med* **103**: 552–557.
- Koob GF, Volkow ND (2010). Neurocircuitry of addiction. *Neuropsychopharmacology* **35**: 217–238.
- Levrano O, Londono D, O'Hara K, Nielsen DA, Peles E, Rotrosen J et al (2008). Genetic susceptibility to heroin addiction: a candidate gene association study. *Genes Brain Behav* **7**: 720–729.
- Li MD (2008). Identifying susceptibility loci for nicotine dependence: 2008 update based on recent genome-wide linkage analyses. *Hum Genet* **123**: 119–131.
- Li MD, Cheng R, Ma JZ, Swan GE (2003). A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. *Addiction* **98**: 23–31.
- Li MD, Xu Q, Lou XY, Payne TJ, Niu T, Ma JZ (2009). Association and interaction analysis of variants in CHRNA5/CHRNA3/CHRNA4 gene cluster with nicotine dependence in African and European Americans. *Am J Med Genet Part B* **5**: 745–756.
- Li MD, Yoon D, Lee JY, Han BG, Niu T, Payne TJ et al (2010). Associations of variants in CHRNA5/A3/B4 gene cluster with smoking behaviors in a Korean population. *PLoS One* **16**: e12183.
- Maes HH, Sullivan PF, Bulik CM, Neale MC, Prescott CA, Eaves LJ et al (2004). A twin study of genetic and environmental influences on tobacco initiation, regular tobacco use and nicotine dependence. *Psychol Med* **34**: 1251–1261.
- Melnikova VI, Raison D, Hardin-Pouzet H, Ugrumov MV, Calas A, Grange-Messent V (2006). Noradrenergic regulation of galanin expression in the supraoptic nucleus in the rat hypothalamus. An *ex vivo* study. *J Neurosci Res* **83**: 857–863.
- Narasimhaiah R, Kamens HM, Picciotto MR (2009). Effects of galanin on cocaine-mediated conditioned place preference and ERK signaling in mice. *Psychopharmacology (Berl)* **204**: 95–102.
- Novak G, Boukhadra J, Shaikh SA, Kennedy JL, Le Foll B (2009). Association of a polymorphism in the NRXN3 gene with the degree of smoking in schizophrenia: a preliminary study. *World J Biol Psychiatry* **10**(Part 3): 929–935.
- Nussbaum J, Xu Q, Payne TJ, Ma JZ, Huang W, Gelernter J et al (2008). Significant association of the neurexin-1 gene (NRXN1) with nicotine dependence in European- and African-American smokers. *Hum Mol Genet* **17**: 1569–1577.

- O'Malley SS, Cooney JL, Krishnan-Sarin S, Dubin JA, McKee SA, Cooney NL *et al* (2006). A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. *Arch Intern Med* **166**: 667–674.
- Pergadia ML, Agrawal A, Loukola A, Montgomery GW, Broms U, Saccone SF *et al* (2009). Genetic linkage findings for DSM-IV nicotine withdrawal in two populations. *Am J Med Genet B* **150B**: 950–959.
- Pergadia ML, Heath AC, Martin NG, Madden PA (2006). Genetic analyses of DSM-IV nicotine withdrawal in adult twins. *Psychol Med* **36**: 963–972.
- Perkins KA, Lerman C, Mercincavage M, Fonte CA, Briski JL (2009). Nicotinic acetylcholine receptor beta2 subunit (CHRN2) gene and short-term ability to quit smoking in response to nicotine patch. *Cancer Epidemiol Biomarkers Prev* **18**: 2608–2612.
- Piasecki TM (2006). Relapse to smoking. *Clin Psychol Rev* **26**: 196–215.
- Picciotto MR, Brabant C, Einstein EB, Kamens HM, Neugebauer NM (2010). Effects of galanin on monoaminergic systems and HPA axis: potential mechanisms underlying the effects of galanin on addiction- and stress-related behaviors. *Brain Res* **1314**: 206–218.
- Pritchard JK, Stephens M, Donnelly P (2000a). Inference of population structure using multilocus genotype data. *Genetics* **155**: 945–959.
- Pritchard JK, Stephens M, Rosenberg NA, Donnelly P (2000b). Association mapping in structured populations. *Am J Hum Genet* **67**: 170–181.
- Radloff LS (1977). The CES-D scale: a self-report depression scale for research in the general population. *Appl Psychol Measure* **1**: 385–401.
- Robinson JK, Brewer A (2008). Galanin: a potential role in mesolimbic dopamine-mediated instrumental behavior. *Neurosci Biobehav Rev* **32**: 1485–1493.
- Rosenberg N, Murata M, Ikeda Y, Opare-Sem O, Zivelin A, Geffen E *et al* (2002). The frequent 5,10-methylenetetrahydrofolate reductase C677T polymorphism is associated with a common haplotype in whites, Japanese, and Africans. *Am J Hum Genet* **70**: 758–762.
- Saccone NL, Wang JC, Breslau N, Johnson EO, Hatsukami D, Saccone SF *et al* (2009). The CHRNA5-CHRNA3-CHRN2B4 nicotinic receptor subunit gene cluster affects risk for nicotine dependence in African-Americans and in European-Americans. *Cancer Res* **69**: 6848–6856.
- Saccone SF, Hinrichs AL, Saccone NL, Chase GA, Konvicka K, Madden PA *et al* (2007). Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. *Hum Mol Genet* **16**: 36–49.
- Stern MC, Conti DV, Siegmund KD, Corral R, Yuan JM, Koh WP *et al* (2007). DNA repair single-nucleotide polymorphisms in colorectal cancer and their role as modifiers of the effect of cigarette smoking and alcohol in the Singapore Chinese Health Study. *Cancer Epidemiol Biomarkers Prev* **16**: 2363–2372.
- Stevens VL, Bierut LJ, Talbot JT, Wang JC, Sun J, Hinrichs AL *et al* (2008). Nicotinic receptor gene variants influence susceptibility to heavy smoking. *Cancer Epidemiol Biomarkers Prev* **17**: 3517–3525.
- Teneggi V, Tiffany ST, Squassante L, Milleri S, Ziviani L, Bye A (2005). Effect of sustained-release (SR) bupropion on craving and withdrawal in smokers deprived of cigarettes for 72 h. *Psychopharmacology (Berl)* **183**: 1–12.
- Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP *et al* (2008). A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. *Nature* **452**: 638–642.
- Tiffany ST, Warthen MW, Goedeker KC (2009). The functional significance of craving in nicotine dependence. *Nebr Symp Motiv* **55**: 171–197.
- Toll BA, O'Malley SS, Katulak NA, Wit R, Dubin JA, Latimer A *et al* (2007a). Comparing gain- and loss-framed messages for smoking cessation with sustained-release bupropion: a randomized controlled trial. *Psychol Addict Behav* **21**: 534–544.
- Tobacco and Genetics Consortium (2010). Genome-wide meta-analyses identify multiple loci associated with smoking behavior. *Nat Genet* **42**: 441–447.
- Toll BA, O'Malley SS, McKee SA, Salovey P, Krishnan-Sarin S (2007b). Confirmatory factor analysis of the Minnesota Nicotine Withdrawal Scale. *Psychol Addict Behav* **21**: 216–225.
- Toll BA, White M, Wu R, Meandzija B, Jatlow P, Makuch R *et al* (2010). Low-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: a randomized trial. *Drug Alcohol Depend* **111**: 200–206.
- True WR, Heath AC, Scherrer JF, Waterman B, Goldberg J, Lin N *et al* (1997). Genetic and environmental contributions to smoking. *Addiction* **92**: 1277–1287.
- Uhl GR, Drgon T, Johnson C, Ramoni MF, Behm FM, Rose JE (2010). Genome wide association for smoking cessation success in a trial of precessation nicotine replacement. *Mol Med* **2010**: 00052.
- Uhl GR, Liu QR, Drgon T, Johnson C, Walther D, Rose JE *et al* (2008). Molecular genetics of successful smoking cessation: convergent genome-wide association study results. *Arch Gen Psychiatry* **65**: 683–693.
- Uhl GR, Liu QR, Drgon T, Johnson C, Walther D, Rose JE (2007). Molecular genetics of nicotine dependence and abstinence: whole genome association using 520,000 SNPs. *BMC Genet* **8**: 10.
- Weiss RB, Baker TB, Cannon DS, von Niederhausern A, Dunn DM, Matsunami N *et al* (2008). A candidate gene approach identifies the CHRNA5-A3-B4 region as a risk factor for age-dependent nicotine addiction. *PLoS Genet* **4**: e1000125.
- World Health Organization (2008). *The World Health Statistic: Reducing Deaths from Tobacco*. World Health Organization (WHO): Geneva, Switzerland.
- Xian H, Scherrer JF, Madden PA, Lyons MJ, Tsuang M, True WR *et al* (2003). The heritability of failed smoking cessation and nicotine withdrawal in twins who smoked and attempted to quit. *Nicotine Tob Res* **5**: 245–254.
- Zachariou V, Georgescu D, Kansal L, Merriam P, Picciotto MR (2001). Galanin receptor 1 gene expression is regulated by cyclic AMP through a CREB-dependent mechanism. *J Neurochem* **76**: 191–200.
- Zachariou V, Parikh K, Picciotto MR (1999). Centrally administered galanin blocks morphine place preference in the mouse. *Brain Res* **831**: 33–42.
- Zachariou V, Thome J, Parikh K, Picciotto MR (2000). Upregulation of galanin binding sites and GalR1 mRNA levels in the mouse locus coeruleus following chronic morphine treatments and precipitated morphine withdrawal. *Neuropsychopharmacology* **23**: 127–137.

Supplementary Information accompanies the paper on the Neuropsychopharmacology website (<http://www.nature.com/npp>)